Русский
Experience with UroBest® in patients with acute cystitis
DOI: https://dx.doi.org/10.18565/urology.2024.4.41-47
Kyzlasov P.S., Neymark B.A., Kuzmenko A.V., Abuev G.G., Gyaurgiev T.A., Kuzmenko G.A.
1) A.I. Burnazyan SRC FMBC, FMBA of Russia, Moscow, Russia; 2) Altai State Medical University of the Ministry of Health of the Russian Federation, Barnaul, Russia 3) Voronezh State Medical University named after N.N. Burdenko
Aim. To evaluate the efficacy and safety of UroBest® complex in sachets for combined therapy of patients with acute cystitis in comparison with products of similar composition.
Materials and Methods. The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest® 1 sachet daily for 7 days from the first day of therapy, NefroBest-N® one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest® complex in the first week. In group 2, UroBest® 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) "Uronext"® 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.
Results. The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.
Conclusion. UroBest® has a favorable efficacy and safety profile. According to our experience, combination of UroBest® and NefroBest-N® complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest® as monotherapy and, to an even greater extent, to the biologically active supplement UroNext®.
Materials and Methods. The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest® 1 sachet daily for 7 days from the first day of therapy, NefroBest-N® one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest® complex in the first week. In group 2, UroBest® 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) "Uronext"® 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.
Results. The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.
Conclusion. UroBest® has a favorable efficacy and safety profile. According to our experience, combination of UroBest® and NefroBest-N® complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest® as monotherapy and, to an even greater extent, to the biologically active supplement UroNext®.
About the Autors
Corresponding author: G.G. Abuev – urologist, Ph.D. student at the Department of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia, Moscow, Russia, e-mail: abuev.urology@gmail.com
Similar Articles
